IP Library Granted Patent US 12,098,367
Granted Patent B2
US 12,098,367 · App. 16/978,428 · Granted Sep 24, 2024

Argonaute protein mutant and use thereof

Inventors: Jianguang Zhang (Beijing, CN); Aiping Mao (Beijing, CN)
Assignee: BERRY GENOMICS CO., LTD.
C12N15/1093C07K14/195C12N9/22C07K2319/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,367
App. No.
16/978,428
Granted
Sep 24, 2024
Kind
B2
Abstract

The present invention relates to a mutant of Argonaute protein lacking a DNA cleavage activity but having a DNA binding activity, wherein the mutation of the mutant is located in a PIWI domain. The present invention also relates to a use based on the protein mutant, especially in enrichment of a target DNA and construction of sequence libraries. Therefore, the present invention also relates to a method for enrichment of a target DNA, comprising the following steps: (a) designing a guide sequence for a specific sequence in the target DNA; (b) binding the mutant according to the present invention, the guide sequence and the target DNA to obtain a mutant-guide sequence-target DNA ternary complex; (c) capturing the mutant-guide sequence-target DNA ternary complex through a capture medium; and (d) separating the target DNA from the captured mutant-guide sequence-target DNA ternary complex to obtain an enriched target DNA.

Claims (21)

1. A mutant of Argonaute protein, having a DNA binding activity but lacking a DNA cleavage activity, wherein the mutation of the mutant is located in a PIWI domain, wherein the amino acid sequence of the Argonaute protein is as shown in SEQ ID NO: 1, and wherein amino acids at positions 628-770 of SEQ ID NO: 1 are deleted.

2. The mutant of claim 1 , wherein the mutant further comprises mutations located in the following domains: N-terminal domain and PAZ domain.

3. A method for enrichment of a target DNA comprising the following steps:

(a) designing a guide sequence for a specific sequence in the target DNA;

(b) binding the mutant of claim 1 , the guide sequence and the target DNA to obtain a mutant-guide sequence-target DNA ternary complex;

(c) capturing the mutant-guide sequence-target DNA ternary complex through a capture medium;

(d) separating the target DNA from the captured mutant-guide sequence-target DNA ternary complex to obtain an enriched target DNA.

4. The method of claim 3 , wherein the step (b) further comprises the following steps:

(b1) binding the mutant of claim 1 with a guide sequence to obtain a mutant-guide sequence binary complex;

(b2) binding the mutant-guide sequence binary complex with the target DNA sequence to obtain a mutant-guide sequence-target DNA ternary complex.

5. The method of claim 3 , wherein the guide sequence is a DNA.

6. The method of claim 3 , wherein the guide sequence is a single stranded DNA (ssDNA).

7. The method of claim 3 , wherein the guide sequence comprises nucleotide modifications.

8. The method of claim 7 , wherein the modification is 5′ phosphorylation or 5′ hydroxylation.

9. The method of claim 3 , wherein the guide sequence has a length of 15-25 nucleotides.

10. The method of claim 3 , wherein the guide sequence is substantially complementary to the specific sequence in the target DNA.

11. The method of claim 3 , wherein the capture medium is magnetic beads.

12. The method of claim 3 , wherein the capture medium carries a capture tag capable of binding to the specific tag carried by the mutant.

13. A kit comprising the mutant of claim 1 .

14. The kit of claim 13 , further comprising a guide sequence and a capture medium.

15. The kit of claim 14 , wherein the guide sequence is a DNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: ZHANG, JIANGUANG; MAO, AIPING
To: BERRY GENOMICS CO., LTD.
Reel/Frame 053974/0485 →
Priority Claims (2)
CN 201810184689.6 · Mar 6, 2018 · national
CN 201811505553.7 · Dec 10, 2018 · national
Continuity (1)
Related Publication 20210332353A1 · Oct 28, 2021